Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | unspecified VEGF antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| unspecified VEGF antibody |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07504588 | Phase II | unspecified VEGF antibody Bevacizumab + Sacituzumab govitecan-hziy Bevacizumab + Carboplatin + Gemcitabine Bevacizumab Carboplatin + Pegylated liposomal doxorubicin + unspecified VEGF antibody Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin Sacituzumab govitecan-hziy + unspecified VEGF antibody Carboplatin + Gemcitabine + unspecified VEGF antibody | Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | Recruiting | USA | 0 |